Novartis Secures $3.2 Billion Licensing Deal for Subcutaneous Drug Delivery
The Swiss pharmaceutical giant partners with Alteogen to leverage advanced enzyme technology for the transition of intravenous biologics to subcutaneous delivery.

The human gut microbiome acts as a complex metabolic engine, but recent findings suggest that when dietary fiber is scarce, these microbial populations may begin to consume the host’s own protective mucus lining. This discovery, detailed in research led by Jenna AbuSalim and Joshua Rabinowitz at Ludwig Princeton, highlights a critical mechanism where the absence of specific plant-derived nutrients forces bacteria to turn inward for sustenance.
The study published in the Proceedings of the National Academy of Sciences identifies a class of nutrients termed proteins imitating fiber, or Prif, which play a significant role in this process. These indigestible plant proteins, alongside traditional fiber, appear to shift the metabolic output of the microbiome away from harmful compounds and toward beneficial ones.
When these nutrients are abundant, the bacterial consumption of host-derived proteins—such as those found in the intestinal mucus—decreases significantly. Researchers utilized stable isotope tracing in mouse models to observe these metabolic shifts in real-time, providing a clear view of how diet dictates bacterial behavior.
The data indicates that harmful phenol metabolites, which have been linked to systemic toxicity and cancer progression, are primarily produced when gut bacteria are forced to digest host tissues. Conversely, the presence of Prif and fiber provides the necessary substrate for bacteria to produce healthful metabolites like phenylpropionate.
This shift suggests that the composition of the gut environment is highly sensitive to the specific types of plant proteins consumed by the host. By labeling proteins with stable isotopes, the team successfully traced the origin of these compounds, confirming that fiber acts as a protective barrier against the degradation of the gut lining.
A second study published in Nature Metabolism challenges the long-held assumption that all phenol and indole metabolites are exclusively the product of microbial activity. By using isotope tracing across mice, rats, and human cells, the team demonstrated that mammalian metabolism is capable of producing many of these compounds independently.
This finding complicates the current understanding of how dietary interventions influence circulating metabolite levels in the human body. The research indicates that while some metabolites like indole-3-propionate are strictly microbial, others like indole-3-lactate are produced by the host.
This distinction is vital for researchers attempting to design targeted therapies for diseases ranging from inflammatory bowel disease to cancer. Antibiotic treatments, which disrupt the microbiome, were shown to reduce microbial-exclusive metabolites while leaving host-produced compounds largely unaffected.
These studies collectively suggest that the therapeutic potential of diet lies in the precise control of microbial outputs. By understanding which specific dietary components influence the production of beneficial versus harmful metabolites, clinicians may eventually offer more refined nutritional guidance.
The identification of Prif as a distinct nutrient class provides a new framework for evaluating how plant-based diets impact long-term metabolic health. This research offers a roadmap for future dietary, probiotic, or metabolic interventions designed to optimize human health.
The implications for disease prevention are significant, as the interaction between diet and the microbiome is increasingly recognized as a foundational element of human physiology. Future interventions may move beyond broad dietary recommendations toward personalized protocols that account for both microbial and host metabolic contributions.
This shift in perspective underscores the need for a more granular approach to how we define and measure the health benefits of plant-based nutrition. The research team emphasizes that the ability of the host to produce essential metabolites may serve as a buffer against microbiome disruptions.
However, the reliance on dietary fiber and Prif remains a critical factor in maintaining the integrity of the gut lining and overall metabolic homeostasis. As scientists continue to map these complex pathways, the focus will likely shift toward identifying the specific food sources that most effectively optimize these dual metabolic systems.
The Swiss pharmaceutical giant partners with Alteogen to leverage advanced enzyme technology for the transition of intravenous biologics to subcutaneous delivery.
Forensic scientists are refining techniques to turn bacterial traces into reliable evidence, aiming to bridge the gap in investigations where traditional DNA fails.
Personalized medicine’s AI often misses the individual, relying on population data. Now, startups are training AI on direct biological data, like the microbiome, to deliver truly adaptive and precise treatments, shifting healthcare from statistics to understanding unique human biology.